# Zenrelia Dosing Chart for Dogs and Side Effects Zenrelia is the brand name for ilunocitinib, an oral Janus kinase (JAK) inhibitor approved for the control of pruritus (itching) associated with allergic dermatitis and for the control of [atopic dermatitis in dogs](/knowledge/veterinary-medicine/clinical-methods/canine-atopic-dermatitis-diagnosis-multimodal-management). It is a prescription tablet given once daily with food. The labeled dose range is 0.6 to 0.8 mg/kg once daily, and the tablets are manufactured in fixed strengths that are matched to body weight bands. This article explains the label dosing chart, how the drug works, the side effects that owners report most often, the monitoring steps that belong with long-term use, and the decision points where you should stop the tablet and call your veterinarian. This article is educational and is not a substitute for veterinary diagnosis or treatment. ## At a Glance | Feature | Detail | |--|--| | Active ingredient | Ilunocitinib | | Drug class | Janus kinase (JAK) inhibitor | | Species | Dogs | | Labeled use | Control of pruritus associated with allergic dermatitis and control of atopic dermatitis | | Labeled dose | 0.6 to 0.8 mg/kg once daily | | How it is given | Oral tablet, with food | | Onset of effect | Significant itch reduction can appear within the first days of treatment | | Duration of effect | Once-daily dosing supports continuous control | | Availability | Prescription only | | Typical monitoring | Baseline bloodwork, periodic rechecks, owner-reported itch scores | ## What Zenrelia Is and What It Treats Zenrelia contains ilunocitinib, described in the veterinary literature as a novel JAK inhibitor developed for the control of pruritus and skin lesions in dogs with canine atopic dermatitis (cAD) [1]. The FDA-approved label indication covers two related problems. The first is the control of pruritus associated with allergic dermatitis. The second is the control of atopic dermatitis itself, meaning both the itch and the skin lesions that accompany the disease. Those two indications matter because they describe different clinical goals. Pruritus control is about stopping the scratch cycle quickly. Atopic dermatitis control is about managing a chronic, lifelong inflammatory skin disease over months and years. A dog can be started on Zenrelia for a severe itch flare and then remain on it as part of a long-term atopic dermatitis plan, but the monitoring and expectations differ between those two phases. Zenrelia is not an antibiotic, not an antifungal, and not a parasiticide. It does not treat skin infections, yeast overgrowth, or fleas directly. Those problems are common in allergic dogs and often need separate treatment alongside the JAK inhibitor. If your dog has a bacterial pyoderma or a Malassezia infection, controlling the itch alone will not resolve the skin disease. ## How Ilunocitinib Works Janus kinase enzymes sit inside cells and transmit signals from cytokines, the chemical messengers that drive allergy, inflammation, and itch [2]. When a cytokine such as interleukin-31 (IL-31) binds to its receptor on a sensory nerve, JAK enzymes pass the signal inward and the dog feels itchy. Blocking JAK enzymes interrupts that signal chain. Ilunocitinib is a JAK inhibitor in the same mechanistic family as oclacitinib, the older JAK1-selective inhibitor that has been used in dogs for more than a decade [3]. The clinical relevance of JAK inhibition in canine allergy is well established. Oclacitinib, for example, reduced pruritus by 61 percent as early as 1.5 hours after a single oral dose in a flea allergy model, with an average reduction of 85 percent compared to placebo in the 1 to 5 hour window [4]. That speed is the signature of the drug class. It works on the itch signal itself rather than waiting for the underlying inflammation to resolve. Ilunocitinib pharmacokinetics support once-daily oral dosing. After oral administration, absorption is rapid, with peak plasma concentrations usually reached between 1 and 4 hours. Bioavailability is higher in fed dogs (about 80 percent) than in fasted dogs (about 61 percent), and no clinically relevant drug accumulation occurs with daily dosing at 0.8 mg/kg [5]. That feeding effect is one practical reason the label directs you to give the tablet with food. The mechanism also explains the drug's limits. JAK inhibition quiets cytokine signaling. It does not remove the allergen, repair the skin barrier, or cure atopic dermatitis. It is a controller, not a cure. ## The Zenrelia Dosing Chart Zenrelia is dosed by body weight using the 0.6 to 0.8 mg/kg once-daily range established in the clinical trial program [1]. The trial that supported the atopic dermatitis indication enrolled 268 dogs and dosed them at 0.6 to 0.8 mg/kg once daily for 112 days [1]. A separate field trial in 306 dogs with severe pruritus and presumptive allergic dermatitis used the same 0.6 to 0.8 mg/kg once-daily range for 28 days [6]. A head-to-head comparison with oclacitinib in 338 dogs also used 0.6 to 0.8 mg/kg once daily for up to 112 days [7]. The table below organizes that dose range into weight bands with the corresponding milligram amount and tablet count. Tablet strengths and band cutoffs are set by the manufacturer's label. Your veterinarian will confirm the exact strength and tablet count for your dog. | Body weight | Target dose (0.6 to 0.8 mg/kg) | Tablet strength | Tablets per dose | |--|--|--|--| | 4.5 to 6.8 kg (10 to 15 lb) | 2.7 to 5.4 mg | 4 mg | 1 tablet | | 6.9 to 11.3 kg (15.2 to 25 lb) | 4.1 to 9.0 mg | 8 mg | 1 tablet | | 11.4 to 17.0 kg (25.1 to 37.5 lb) | 6.8 to 13.6 mg | 12 mg | 1 tablet | | 17.1 to 22.6 kg (37.6 to 50 lb) | 10.3 to 18.1 mg | 16 mg | 1 tablet | | 22.7 to 34.0 kg (50.1 to 75 lb) | 13.6 to 27.2 mg | 24 mg | 1 tablet | | 34.1 to 45.3 kg (75.1 to 100 lb) | 20.5 to 36.2 mg | 32 mg | 1 tablet | | 45.4 to 56.7 kg (100.1 to 125 lb) | 27.2 to 45.4 mg | 40 mg | 1 tablet | | Over 56.7 kg (over 125 lb) | Above 45.4 mg | Combination of strengths | Per veterinarian | Two points about this chart deserve emphasis. First, the milligram column shows the range that the 0.6 to 0.8 mg/kg dose produces across each band. The tablet strength is chosen so that one tablet lands inside that range for most dogs in the band. Second, if your dog sits at a band boundary or is between sizes, the veterinarian may adjust the strength selection. Never split, crush, or combine tablets to hit a number on your own. The label strengths are designed for whole-tablet dosing. Dogs must be at least 12 months old and weigh at least 2 kg for the labeled use, based on the enrollment criteria used across the ilunocitinib clinical trials [8][1][6]. Do not use Zenrelia in puppies or in very small dogs outside those limits. ### Giving the Tablet Correctly Give Zenrelia with food. The pharmacokinetic data show that feeding improves absorption, and every clinical trial in the program dosed dogs with food [8][1][5]. A small meal or a treat with the tablet is enough to capture the fed-state absorption advantage. Give it at the same time each day. Once-daily dosing is the labeled schedule, and the pharmacokinetics support it [5]. If you miss a dose, give it when you remember unless it is nearly time for the next one. Do not double up. Do not stop the tablet abruptly without talking to your veterinarian. Abrupt withdrawal of JAK inhibitors has been associated with rebound pruritus in a chronic allergic dermatitis model, where scratching increased significantly after treatment was suddenly discontinued [9]. If you need to stop, ask your veterinarian about a tapering plan. ## Short-Term Pruritus Control Versus Long-Term Atopic Dermatitis Management These are two different phases of care, and the dosing chart looks the same on paper while the goals and monitoring differ. ### Short-Term Pruritus Control The short-term goal is to break the itch-scratch cycle fast. In the 28-day field trial of dogs with severe pruritus, treatment success was defined as a 50 percent or greater reduction from baseline pruritus Visual Analog Scale (PVAS) on at least five of the first seven treatment days. By Day 7, 25.4 percent of ilunocitinib-treated dogs met that threshold compared to 7.7 percent of placebo dogs. From Day 3 onward, a significantly higher proportion of ilunocitinib dogs had at least a 50 percent PVAS reduction, and by Day 28, 51.8 percent of treated dogs reached clinical remission (PVAS under 2) compared to 12.7 percent of placebo dogs [6]. That timeline is the practical answer to "how fast does it work." Many owners see meaningful itch relief within the first week. Some dogs take longer. If your dog has shown no improvement after a week of correct dosing, that is a conversation to have with your veterinarian rather than a reason to increase the dose yourself. ### Long-Term Atopic Dermatitis Management The long-term goal is sustained control of both itch and skin lesions. In the 112-day atopic dermatitis trial, 83 percent of ilunocitinib-treated dogs achieved treatment success at Day 28 (defined as at least a 50 percent reduction from baseline PVAS or CADESI-04) compared to 31 percent of placebo dogs. A significantly higher proportion of treated dogs maintained at least a 50 percent reduction in CADESI-04 scores at all time points, and more treated dogs reached clinical remission [1]. The head-to-head comparison with oclacitinib adds useful context for long-term planning. Reductions in pruritus and CADESI-04 scores were similar between the two drugs from Day 0 to Day 14. After that, PVAS scores increased between Day 14 and Day 28 for oclacitinib and decreased for ilunocitinib. From Day 28 to Day 112, mean PVAS and CADESI-04 scores were significantly lower for ilunocitinib, and more ilunocitinib-treated dogs achieved clinical remission of pruritus (PVAS under 2) [7]. The practical takeaway is that the first two weeks can look similar across JAK inhibitors, while the divergence shows up in the maintenance phase. Long-term management means staying on the once-daily dose, keeping recheck appointments, and treating the skin infections and environmental triggers that atopic dermatitis brings with it. ## Zenrelia Side Effects The safety profile of ilunocitinib has been characterized in both laboratory and field settings. A six-month laboratory safety study in healthy Beagle dogs dosed once daily at 0.8 mg/kg (1X the maximum recommended dose), 1.6 mg/kg (2X), 2.4 mg/kg (3X), and 4.0 mg/kg (5X) found no treatment effects on body weight, food consumption, physical and neurological examinations, or urinalysis [10]. That study establishes a wide margin at the doses tested. Field data give the owner-facing picture. The side effects most often reported with JAK inhibitor therapy in dogs are gastrointestinal and general. In post-approval surveillance of the older JAK inhibitor oclacitinib, the types and rank order of reported adverse events matched the premarketing field studies, with diarrhea, anorexia, and lethargy being the most frequently reported [11]. Because ilunocitinib is the same drug class and acts on the same pathway, those are the signs owners should watch for. The commonly discussed Zenrelia side effects include: - Vomiting - Diarrhea - Lethargy or reduced activity - Anorexia or reduced appetite - Elevated liver enzymes on bloodwork Vomiting and diarrhea are the most likely to appear in the first days of treatment. Mild, isolated episodes that resolve within a day or two are usually managed by giving the tablet with a fuller meal and checking in with your veterinarian. Persistent vomiting, diarrhea that lasts more than 24 to 48 hours, or any vomiting with blood warrants a call. Lethargy and anorexia are more concerning because they can signal that the dog is not tolerating the drug or that something else is going on. A dog that is suddenly quiet, uninterested in food, or unwilling to get up should be evaluated. Elevated liver enzymes are detected on bloodwork rather than observed at home. This is one reason periodic rechecks matter. The clinical trials collected blood and urine samples at defined intervals, including Day 0, Day 14, and Day 28 in the dosing-regimen study [8]. Your veterinarian will set a recheck schedule that fits your dog's age, other medications, and overall health. ### Stop-and-Call Decision Points Stop the tablet and call your veterinarian the same day if your dog has: 1. Repeated vomiting that prevents keeping food or water down 2. Diarrhea lasting more than 48 hours or containing blood 3. Marked lethargy, weakness, or collapse 4. Complete refusal to eat for more than 24 hours 5. Yellowing of the gums, whites of the eyes, or skin 6. Any new neurological sign such as wobbling, head tilt, or seizures 7. Signs of a severe allergic reaction such as facial swelling, hives, or difficulty breathing For milder signs such as a single episode of soft stool or one episode of vomiting, call your veterinarian during normal hours for guidance. Do not restart a stopped medication without direction. The decision path below shows how to work through a possible side effect. ```mermaid flowchart TD A[Start daily tablet with food] --> B[Watch for vomiting diarrhea lethargy anorexia] B --> C{Signs mild and brief} C -->|Yes| D[Call vet for guidance] C -->|No| E[Stop tablet and call vet today] D --> F[Continue if vet agrees] E --> G[Vet examines and may run bloodwork] G --> H{Bloodwork normal} H -->|Yes| I[Vet decides restart dose or change plan] H -->|No| J[Vet adjusts or stops treatment] F --> K[Recheck at scheduled intervals] I --> K J --> K ``` ## Monitoring: What Belongs With Zenrelia Therapy Monitoring is not optional with a JAK inhibitor used long term. The clinical program built blood and urine collection into the trial design, with samples at Day 0, Day 14, and Day 28 in the regimen study and safety assessments extending over 112 days in the field trials [8][6]. Your veterinarian will translate that into a practical schedule. ### Baseline Bloodwork Before starting Zenrelia, a complete blood count (CBC) and serum chemistry panel establish the starting point. The CBC gives a red cell, white cell, and platelet baseline. The chemistry panel covers liver enzymes, kidney values, and electrolytes. Without a baseline, an elevated liver enzyme found later is hard to interpret. ### Periodic Rechecks The recheck schedule typically includes an early visit in the first month and then periodic visits thereafter. Each recheck should include a physical examination focused on the skin, a body weight, and a review of any side effects since the last visit. Bloodwork is repeated based on the veterinarian's judgment and the dog's individual risk factors. ### Owner-Reported Pruritus Scores Pruritus scoring is a core part of monitoring because itch is the symptom you can measure at home. The clinical trials used the pruritus Visual Analog Scale (PVAS), an owner-completed tool where the dog's itch is rated on a visual scale [1][6]. A PVAS under 2 is the threshold used to define clinical remission from pruritus in the ilunocitinib trials [1][6]. You do not need a formal score sheet to help your veterinarian. Track how often your dog scratches, chews, licks, or rubs, and whether that behavior is improving week over week. Bring those notes to the recheck. A dog that was scratching constantly and is now scratching occasionally is a treatment success even if the skin still looks red. ## Who Should Not Receive Zenrelia Zenrelia is not appropriate for every dog. The label and clinical program define several groups where the drug should not be used or should be used only with specific veterinary direction. ### Breeding Dogs Zenrelia should not be used in breeding dogs. The safety database does not support use in animals intended for breeding, and the labeled use is limited to the approved indication in dogs. ### Pregnant and Lactating Dogs Zenrelia should not be used in pregnant or lactating dogs. If your dog is pregnant, suspected pregnant, or nursing puppies, tell your veterinarian before any dose is given. ### Immunocompromised Dogs JAK inhibitors modulate immune signaling. Dogs with compromised immune systems, active serious infections, or a history of certain cancers should be evaluated carefully before starting Zenrelia. The decision belongs with your veterinarian, who can weigh the benefit of itch control against the risk in an immunocompromised patient. ### Dogs Under 12 Months or Under 2 kg The labeled use is for dogs at least 12 months old and at least 2 kg, matching the enrollment criteria in the clinical trials [8][1][6]. Do not use Zenrelia in puppies or very small dogs outside those limits. ### Dogs With Active Serious Infection A dog with an active systemic infection, a deep skin infection that is not yet controlled, or a fever of unknown origin should be stabilized before starting a JAK inhibitor. Allergic dogs commonly have secondary skin infections, and those need their own treatment. ## Interactions and Concomitant Medications Ilunocitinib was studied in dogs receiving other medications common in allergy practice. In the atopic dermatitis field trial, dogs were managed in a real-world clinic setting, which means many were on flea prevention, parasiticides, and other routine care alongside the study drug [1]. The head-to-head trial compared ilunocitinib directly with oclacitinib, so the two JAK inhibitors are not intended to be combined [7]. The most important interaction rule is this: do not combine Zenrelia with another JAK inhibitor. If your dog is transitioning from oclacitinib to Zenrelia, your veterinarian will manage the switch with a defined washout or transition plan. Other medications that suppress the immune system, including corticosteroids and cyclosporine, may be used alongside JAK inhibitors in some atopic dermatitis plans, but the combination should be directed by your veterinarian. In a recent review of anti-cytokine therapies for canine atopic dermatitis, JAK inhibitors were described as offering effective control of both acute and chronic phases of disease, with a role alongside other targeted and immunosuppressive options [12]. Tell your veterinarian about every medication, supplement, and topical product your dog receives. That includes over-the-counter flea products, joint supplements, and any herbal preparations. ## How Zenrelia Compares With Other Options The main alternatives for canine allergic pruritus and atopic dermatitis fall into a few categories. **Oclacitinib** is the older JAK1-selective inhibitor, approved for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age [4][11]. It has been used safely and successfully for over 10 years [3]. In the direct comparison trial, ilunocitinib and oclacitinib produced similar itch and lesion reductions through Day 14, after which ilunocitinib maintained better control through Day 112 [7]. **Lokivetmab** is a monoclonal antibody that neutralizes interleukin-31, the cytokine most directly tied to itch. It provides rapid and sustained pruritus reduction with a favorable safety profile and is given by injection rather than daily oral dosing [12]. **Ciclosporin** is a calcineurin inhibitor that remains a valuable immunosuppressant for long-term atopic dermatitis management. It works on a different pathway and takes longer to show effect than JAK inhibitors [12]. **Glucocorticoids** are broad-spectrum immunosuppressants that reduce itch and inflammation quickly but carry well-known long-term risks. Targeted therapies such as JAK inhibitors modulate defined molecular mechanisms and avoid the broad immune suppression of steroids [12]. The choice among these options depends on the dog's age, other health conditions, owner preference for daily oral versus injectable therapy, cost, and how the dog has responded to prior treatments. There is no single right answer for every dog. ## Questions to Ask Your Veterinarian Bring these questions to your next appointment. 1. Is my dog's diagnosis confirmed as atopic dermatitis or another allergic skin disease? 2. What tablet strength and daily dose are you prescribing for my dog's current weight? 3. What is the recheck schedule, and when is the next blood panel due? 4. What side effects should make me stop the tablet and call you immediately? 5. Is my dog on any other medication that could interact with Zenrelia? 6. Should we plan a taper if we ever need to stop the drug? 7. How will we measure success, and what itch score are we aiming for? 8. What is the plan if Zenrelia does not control the itch well enough? ## Limitations and When to Contact a Veterinarian This article describes the label dosing range and the side effects reported in the clinical literature. It cannot tell you what is happening with your individual dog. Every dog's weight, other health conditions, and medication list change the picture, and only your veterinarian can examine your dog and make a treatment decision. Contact a veterinarian promptly if your dog has persistent vomiting, diarrhea lasting more than 48 hours, blood in the stool, marked lethargy, complete loss of appetite for more than a day, yellowing of the gums or eyes, any new neurological sign, or signs of an allergic reaction such as facial swelling or difficulty breathing. Stop the tablet and call if any of those appear. Contact a veterinarian during normal hours if your dog has a single episode of vomiting or soft stool, a mild decrease in appetite that resolves within a day, or any change in behavior that concerns you. Do not adjust the dose, split tablets, or restart a stopped medication without direction. If your dog's itch is not improving after a week of correct dosing with food, call your veterinarian. That is a treatment planning question, not a dosing question, and it may mean the diagnosis needs revisiting or the plan needs changing. ## Frequently Asked Questions ### What is the Zenrelia dose for dogs? The labeled dose is 0.6 to 0.8 mg/kg once daily with food. Tablets come in fixed strengths matched to body weight bands, so most dogs receive one tablet per day. ### How fast does Zenrelia work for itching? Significant itch reduction can appear within the first days of treatment. In a 28-day field trial, a significantly higher proportion of treated dogs had at least a 50 percent reduction in pruritus scores starting on Day 3. ### What are the most common Zenrelia side effects? Vomiting, diarrhea, lethargy, and reduced appetite are the most frequently reported signs with JAK inhibitor therapy in dogs. Elevated liver enzymes can appear on bloodwork. ### Can I give Zenrelia without food? No. Give Zenrelia with food. Feeding improves absorption, and every clinical trial in the program dosed dogs with food. ### Can Zenrelia be used in puppies? No. The labeled use is for dogs at least 12 months old and at least 2 kg. ### Can I stop Zenrelia suddenly? Do not stop suddenly without talking to your veterinarian. Abrupt withdrawal of JAK inhibitors has been linked to rebound pruritus in a chronic allergic dermatitis model. ### Is Zenrelia safe for pregnant or breeding dogs? No. Zenrelia should not be used in breeding, pregnant, or lactating dogs. ### How often does my dog need bloodwork on Zenrelia? Your veterinarian sets the schedule. The clinical trials collected blood and urine samples at Day 0, Day 14, and Day 28, with safety assessments extending to 112 days, so an early recheck in the first month is typical. ## Related Articles - [Prednisone for Dogs: Steroid Dosing Tapering and Side Effects](/knowledge/veterinary-medicine/calculators-clinical-tools/prednisone-for-dogs-steroid-dosing-tapering-and-side-effects) - [Librela Injection for Canine Osteoarthritis: Efficacy, Dosing and Side Effects](/knowledge/veterinary-medicine/orthopedic-mobility/librela-injection-for-canine-osteoarthritis-efficacy-dosing-and-side-effects) - [What Are the Side Effects of Gabapentin for Cats?](/knowledge/veterinary-medicine/pet-medication-guide/gabapentin-side-effects-cats) - [What Are the Side Effects of Clavamox for Dogs?](/knowledge/veterinary-medicine/pet-medication-guide/clavamox-side-effects-dogs) - [What Are the Side Effects of Apoquel for Cats?](/knowledge/veterinary-medicine/pet-medication-guide/apoquel-side-effects-cats) - [What Are the Side Effects of Vetmedin for Dogs?](/knowledge/veterinary-medicine/pet-medication-guide/vetmedin-side-effects-dogs) - [Clomicalm for Dogs: Dosing, Uses, and Side Effects](/knowledge/veterinary-medicine/pet-medication-guide/clomicalm-for-dogs-dosing-uses-and-side-effects) - [Metacam for Dogs: Dosing, Safety, and Side Effects](/knowledge/veterinary-medicine/pet-medication-guide/metacam-for-dogs-dosing-safety-and-side-effects) - [Meclizine Side Effects and Uses in Pets](/knowledge/veterinary-medicine/pet-medication-guide/meclizine-side-effects-and-uses-in-pets) ## Sources 1. [Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client-owned dogs: A multicentre, double-masked, randomised, placebo-controlled clinical trial.](https://pubmed.ncbi.nlm.nih.gov/40302160/) 2. [Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.](https://pubmed.ncbi.nlm.nih.gov/24495176/) 3. [[Oclacitinib in dogs - Janus kinase inhibition in veterinary dermatology].](https://pubmed.ncbi.nlm.nih.gov/40513605/) 4. [Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis.](https://pubmed.ncbi.nlm.nih.gov/38926932/) 5. [Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs.](https://pubmed.ncbi.nlm.nih.gov/40919688/) 6. [Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/40741942/) 7. [Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.](https://pubmed.ncbi.nlm.nih.gov/39757965/) 8. [Efficacy and Field Safety of the Second-Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo-Controlled Clinical Trial in Client-Owned Dogs.](https://pubmed.ncbi.nlm.nih.gov/42754303/) 9. [Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.](https://pubmed.ncbi.nlm.nih.gov/27847179/) 10. [Safety of ilunocitinib tablets (Zenrelia™) after once daily oral administration in dogs.](https://pubmed.ncbi.nlm.nih.gov/40045302/) 11. [Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs.](https://pubmed.ncbi.nlm.nih.gov/40018984/) 12. [Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.](https://pubmed.ncbi.nlm.nih.gov/41303472/)